NeoImmuneTech Unveils Breakthrough Results for CAR-T Therapy
Exciting Advances in CAR-T Therapy with NT-I7
NeoImmuneTech, Inc. has made remarkable progress in improving CAR-T cell therapies, an innovative treatment aimed at fighting cancers. Interim results from the Phase 1b clinical trial highlighting the combination of NT-I7 (efineptakin alfa) with CAR-T therapy have shed light on the potential this approach holds for enhancing patient care.
Challenges in CAR-T Cell Therapy
While CAR-T therapies represent a significant advancement in cancer treatment, they often struggle with adequate cell expansion and long-term persistence. These factors can limit their efficacy during treatments. With the objective of addressing these challenges, NeoImmuneTech’s recent clinical findings reveal that using NT-I7 following CAR-T cell administration is both safe and well tolerated.
Overview of Clinical Trial NIT-112
The NIT-112 clinical trial focuses on patients diagnosed with Large B-cell Lymphoma (LBCL) who have undergone CAR-T therapies, such as Kymriah, Yescarta, or Breyanzi. Following their CAR-T infusion, participants received NT-I7 treatment 21 days later. The aim is to evaluate not just safety and tolerability but also to explore the recommended Phase 2 dose (RP2D), and the potential of NT-I7 to increase CAR-T expansion and durability.
Stable Safety Profile Observed
Early results from doses 4 and 5 of NT-I7 (360 and 480 µg/kg) show promising outcomes. Importantly, there were no reported cases of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), serious side effects often associated with CAR-T therapies. The observed mild side effects were manageable and affected a majority of the participants to a lesser degree.
Amplification of CAR-T Cells
The administration of NT-I7 significantly boosted CAR-T cell numbers, demonstrated prolonged cell persistence, and increased the proportion of T cells exhibiting a stem-cell memory phenotype. This resulted in an overall response rate (ORR) of 81.1% among participants, contrasting starkly with the 52% ORR observed in earlier studies involving Kymriah.
Insights from the CEO
Dr. Luke Oh, President and CEO of NeoImmuneTech, expressed his enthusiasm about the preliminary results of the NIT-112 study. He highlighted the significance of NT-I7 in amplifying CAR-T cells and its potential positive impact on patient outcomes. NeoImmuneTech plans to explore technology transfer opportunities on NT-I7's combination with CAR-T therapies, indicating a future where these treatments may become even more effective.
Understanding NT-I7 (efineptakin alfa)
NT-I7 is a long-acting human IL-7, crucial for T cell development and sustaining immune responses against chronic antigens like cancer. Its favorable pharmacokinetics/dynamics and safety characteristics make it a prime candidate for combination therapies. Ongoing research is investigating NT-I7’s potential in various cancer types and its use as a vaccine adjuvant.
Get to Know NeoImmuneTech, Inc.
NeoImmuneTech, Inc. is dedicated to advancing T cell-focused immunotherapies and enhancing the fight against infectious diseases. The company prides itself on a strong leadership team with extensive experience in the field. As NeoImmuneTech continues to grow, it remains committed to collaborating with both industry and academic leaders to explore the therapeutic avenues offered by NT-I7.
Frequently Asked Questions
What is the NIT-112 clinical trial about?
The NIT-112 trial investigates the safety and effectiveness of NT-I7 in conjunction with CAR-T cell therapies for patients with Large B-cell Lymphoma.
What are the main results of the interim findings?
Interim results show a stable safety profile for NT-I7, with an ORR of 81.1%, highlighting its potential to improve patient outcomes.
Who is leading NeoImmuneTech?
Dr. Luke Oh serves as the President and CEO, guiding the company’s innovative approach to immunotherapy.
What other clinical applications is NT-I7 being studied for?
NT-I7 is being evaluated not only in hematological malignancies but also in solid tumors and as a vaccine adjuvant.
How does NT-I7 enhance CAR-T therapies?
NT-I7 improves CAR-T cell persistence and expansion, thereby potentially increasing the overall effectiveness of the treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Nova Vision Acquisition Corp. Expands Trust Account for Business Deal
- Zentalis Pharmaceuticals Unveils Promising Azenosertib Findings
- Coinbase Global: A Smart Growth Investment for Your Portfolio
- Financial Insights and Progress for 2024 from Australian Oilseeds
- Major Drilling Reports Successful Annual Shareholder Meeting Results
- Tilray Medical's Breakthrough in Fibromyalgia Pain Relief
- Capco and ESG Collaboration Set to Transform Energy Sector
- Upcoming Conference Call for Valeo Pharma's Q3 Results
- Circle Pharma Unveils Promising Preclinical Findings for CID-078
- Nanoscope Therapeutics Highlights Innovative Gene Therapy Advances
Recent Articles
- Understanding Palantir Technologies amid AI Market Growth
- Prospects for Retail Interactive Kiosk Market Growth
- Electronic Wet Chemicals Market Growth Analysis and Trends
- Exploring the Growth and Trends in Liquid Adhesives Market
- Projected Growth of the Cartesian and Gantry Robots Market
- Clean Motion Welcomes Martin Ericson as New Head of Engineering
- Exciting Opportunities: Upcoming Auction for Treasury Bills
- DFDS A/S Launches Share Buyback Program to Boost Value
- ISS A/S Accelerates Share Buyback Program to Increase Value
- PLAY Airlines Sets Record Load Factor and Expands Routes
- Sydbank's Week 36 Share Buyback Program Insights Revealed
- MGI's CycloneSEQ Technology Revolutionizes Genomic Sequencing
- Trampoline Market Poised for $1.5 Billion Growth by 2035
- Exploring Innovations at the Global Energy Transition Forum
- Discover Convergence 2024: Transforming Supply Chain Solutions
- Citi Analysts Predict Significant Rate Cuts Ahead
- Japanese Hedge Funds Gain Traction Amid Market Resilience
- Downward Trends in Indonesia's Stock Market Performance
- Dell Technologies Soars: S&P 500 Inclusion and Growth Prospects
- Merlin Chain Reigns Supreme as Bitcoin's Leading Layer 2 Solution
- Recent Market Trends: Fear Surges as Major Stocks Drop
- Tech Sector Struggles Despite AI Hype: Investors Weigh In
- Marshall Group's Continued Success in the Audio Industry
- Stocks to Keep an Eye on This Week: Earnings and Moves
- Midea's Indoor Hybrid Heat Pump Revolutionizes Home Heating
- Discover the Exciting Forex Roadshow by SquaredFinancial
- Thailand's Economic Stimulus: $4.2 Billion Handout Initiative
- Exploring the Rise of the Global Chemical Distribution Market
- GTreasury Strengthens Market Position with CashAnalytics Deal
- OKX Introduces Catizen's CATI Token with Exciting Campaign
- InterDigital Set to Drive 6G Insights at Annual Symposium
- Danske Bank's Strategic Move: Share Buy-Back Insights
- Alm. Brand A/S Updates Share Buybacks Effectively
- iPhone 16 Launch Sparks Major Upgrade Anticipation for Apple
- Celebrating Innovations at 2024 GPTIAwards Event in Berlin
- Marshall Group Sees Robust Growth in Recent Quarter
- MainStreaming Welcomes Ian Franklyn as New Chief Revenue Officer
- Empowering ISPs: Strategic Imperatives Unveils Elevate Solution
- MainStreaming Welcomes Ian Franklyn as Chief Revenue Officer
- Marshall Group's Impressive Growth Continues This Quarter
- Seven & i Holdings Responds to Alimentation Couche-Tard Proposal
- Oil Prices Rise Amid Hurricane Fears and Job Data Impact
- Understanding Totalkredit A/S Prepayment Data for Investors
- Eckoh Plc Update: Recent Dealings and Key Information
- Breakthrough Results in Graves’ Disease Treatment by Immunovant
- Wall Street Analysts Update Earnings Predictions for ASO
- Navigating Monetary Policy: Key Questions for the ECB's Future
- Stock Futures Rise Amid Fed Rate Cut Speculations
- FTSE 100 Rallies on Positive Forecast from Entain Group
- European Markets Show Resilience with Positive Start This Week